Ezetimibe reduces urinary albumin excretion in hypercholesterolaemic type 2 diabetes patients with microalbuminuria

T. Nakamura, E. Sato, M. Amaha, Y. Kawagoe, S. Maeda, Hiroyoshi Inoue, S. I. Yamagishi

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Objective: This study investigated the effects of ezetimibe, an inhibitor of intestinal cholesterol absorption, on early phase diabetic nephropathy. Methods: A total of 32 hypercholesterolaemic type 2 diabetes patients with microalbuminuria, defined as a urinary albumin excretion (UAE) ≥ 30 but < 300 mg/g creatinine, were enrolled. Various clinical and laboratory parameters were determined at baseline and after 6 months of treatment with 10 mg/day ezetimibe. Results: Ezetimibe treatment significantly decreased glycated haemoglobin (HbA 1c), low-density lipoprotein-cholesterol (LDL-C), triglycerides and UAE, and significantly increased high-density lipoprotein-cholesterol and albumin. It also decreased the serum level of monocyte chemoattractant protein-1 (MCP-1), but this difference was not statistically significant. Univariate analyses showed a correlation between UAE and body mass index, systolic and diastolic blood pressures, HbA 1c, LDL-C, estimated glomerular filtration rate (inverse), creatinine and MCP-1. Since these parameters may be closely correlated with each other, multiple stepwise regression analysis was performed and demonstrated that HbA 1c and MCP-1 were independent determinants of UAE. Conclusions: Ezetimibe may be a promising therapeutic strategy for improving albumin excretion, partly through its anti-inflammatory properties, and for reducing LDL-C in hypercholesterolaemic type 2 diabetes patients with microalbuminuria.

Original languageEnglish
Pages (from-to)798-803
Number of pages6
JournalJournal of International Medical Research
Volume40
Issue number2
Publication statusPublished - 2012

Fingerprint

Medical problems
Type 2 Diabetes Mellitus
Albumins
Chemokine CCL2
LDL Cholesterol
Creatinine
Anticholesteremic Agents
Blood Pressure
Intestinal Absorption
Blood pressure
Glycosylated Hemoglobin A
Diabetic Nephropathies
Glomerular Filtration Rate
Regression analysis
HDL Cholesterol
Ezetimibe
Triglycerides
Body Mass Index
Anti-Inflammatory Agents
Therapeutics

Keywords

  • Albuminuria
  • Diabetic nephropathy
  • Ezetimibe
  • Hypercholesterolaemia;monocyte chemoattractant protein-1

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry
  • Cell Biology
  • Biochemistry, medical

Cite this

Ezetimibe reduces urinary albumin excretion in hypercholesterolaemic type 2 diabetes patients with microalbuminuria. / Nakamura, T.; Sato, E.; Amaha, M.; Kawagoe, Y.; Maeda, S.; Inoue, Hiroyoshi; Yamagishi, S. I.

In: Journal of International Medical Research, Vol. 40, No. 2, 2012, p. 798-803.

Research output: Contribution to journalArticle

Nakamura, T. ; Sato, E. ; Amaha, M. ; Kawagoe, Y. ; Maeda, S. ; Inoue, Hiroyoshi ; Yamagishi, S. I. / Ezetimibe reduces urinary albumin excretion in hypercholesterolaemic type 2 diabetes patients with microalbuminuria. In: Journal of International Medical Research. 2012 ; Vol. 40, No. 2. pp. 798-803.
@article{f02110587cb84e74a6149cd4fbf6f155,
title = "Ezetimibe reduces urinary albumin excretion in hypercholesterolaemic type 2 diabetes patients with microalbuminuria",
abstract = "Objective: This study investigated the effects of ezetimibe, an inhibitor of intestinal cholesterol absorption, on early phase diabetic nephropathy. Methods: A total of 32 hypercholesterolaemic type 2 diabetes patients with microalbuminuria, defined as a urinary albumin excretion (UAE) ≥ 30 but < 300 mg/g creatinine, were enrolled. Various clinical and laboratory parameters were determined at baseline and after 6 months of treatment with 10 mg/day ezetimibe. Results: Ezetimibe treatment significantly decreased glycated haemoglobin (HbA 1c), low-density lipoprotein-cholesterol (LDL-C), triglycerides and UAE, and significantly increased high-density lipoprotein-cholesterol and albumin. It also decreased the serum level of monocyte chemoattractant protein-1 (MCP-1), but this difference was not statistically significant. Univariate analyses showed a correlation between UAE and body mass index, systolic and diastolic blood pressures, HbA 1c, LDL-C, estimated glomerular filtration rate (inverse), creatinine and MCP-1. Since these parameters may be closely correlated with each other, multiple stepwise regression analysis was performed and demonstrated that HbA 1c and MCP-1 were independent determinants of UAE. Conclusions: Ezetimibe may be a promising therapeutic strategy for improving albumin excretion, partly through its anti-inflammatory properties, and for reducing LDL-C in hypercholesterolaemic type 2 diabetes patients with microalbuminuria.",
keywords = "Albuminuria, Diabetic nephropathy, Ezetimibe, Hypercholesterolaemia;monocyte chemoattractant protein-1",
author = "T. Nakamura and E. Sato and M. Amaha and Y. Kawagoe and S. Maeda and Hiroyoshi Inoue and Yamagishi, {S. I.}",
year = "2012",
language = "English",
volume = "40",
pages = "798--803",
journal = "Journal of International Medical Research",
issn = "0300-0605",
publisher = "Field House Publishing LLP",
number = "2",

}

TY - JOUR

T1 - Ezetimibe reduces urinary albumin excretion in hypercholesterolaemic type 2 diabetes patients with microalbuminuria

AU - Nakamura, T.

AU - Sato, E.

AU - Amaha, M.

AU - Kawagoe, Y.

AU - Maeda, S.

AU - Inoue, Hiroyoshi

AU - Yamagishi, S. I.

PY - 2012

Y1 - 2012

N2 - Objective: This study investigated the effects of ezetimibe, an inhibitor of intestinal cholesterol absorption, on early phase diabetic nephropathy. Methods: A total of 32 hypercholesterolaemic type 2 diabetes patients with microalbuminuria, defined as a urinary albumin excretion (UAE) ≥ 30 but < 300 mg/g creatinine, were enrolled. Various clinical and laboratory parameters were determined at baseline and after 6 months of treatment with 10 mg/day ezetimibe. Results: Ezetimibe treatment significantly decreased glycated haemoglobin (HbA 1c), low-density lipoprotein-cholesterol (LDL-C), triglycerides and UAE, and significantly increased high-density lipoprotein-cholesterol and albumin. It also decreased the serum level of monocyte chemoattractant protein-1 (MCP-1), but this difference was not statistically significant. Univariate analyses showed a correlation between UAE and body mass index, systolic and diastolic blood pressures, HbA 1c, LDL-C, estimated glomerular filtration rate (inverse), creatinine and MCP-1. Since these parameters may be closely correlated with each other, multiple stepwise regression analysis was performed and demonstrated that HbA 1c and MCP-1 were independent determinants of UAE. Conclusions: Ezetimibe may be a promising therapeutic strategy for improving albumin excretion, partly through its anti-inflammatory properties, and for reducing LDL-C in hypercholesterolaemic type 2 diabetes patients with microalbuminuria.

AB - Objective: This study investigated the effects of ezetimibe, an inhibitor of intestinal cholesterol absorption, on early phase diabetic nephropathy. Methods: A total of 32 hypercholesterolaemic type 2 diabetes patients with microalbuminuria, defined as a urinary albumin excretion (UAE) ≥ 30 but < 300 mg/g creatinine, were enrolled. Various clinical and laboratory parameters were determined at baseline and after 6 months of treatment with 10 mg/day ezetimibe. Results: Ezetimibe treatment significantly decreased glycated haemoglobin (HbA 1c), low-density lipoprotein-cholesterol (LDL-C), triglycerides and UAE, and significantly increased high-density lipoprotein-cholesterol and albumin. It also decreased the serum level of monocyte chemoattractant protein-1 (MCP-1), but this difference was not statistically significant. Univariate analyses showed a correlation between UAE and body mass index, systolic and diastolic blood pressures, HbA 1c, LDL-C, estimated glomerular filtration rate (inverse), creatinine and MCP-1. Since these parameters may be closely correlated with each other, multiple stepwise regression analysis was performed and demonstrated that HbA 1c and MCP-1 were independent determinants of UAE. Conclusions: Ezetimibe may be a promising therapeutic strategy for improving albumin excretion, partly through its anti-inflammatory properties, and for reducing LDL-C in hypercholesterolaemic type 2 diabetes patients with microalbuminuria.

KW - Albuminuria

KW - Diabetic nephropathy

KW - Ezetimibe

KW - Hypercholesterolaemia;monocyte chemoattractant protein-1

UR - http://www.scopus.com/inward/record.url?scp=84860493918&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860493918&partnerID=8YFLogxK

M3 - Article

VL - 40

SP - 798

EP - 803

JO - Journal of International Medical Research

JF - Journal of International Medical Research

SN - 0300-0605

IS - 2

ER -